Dogwood Therapeutics Enrolls First 100 Patients In Ongoing HALT-CINP Phase 2b CINP Trial

- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated

ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 100 patients in its ongoing HALT-CINP Phase 2b CINP trial. HALT-CINP remains on track to conduct a prespecified interim analysis during the fourth quarter of 2025 on patients who have completed or been terminated from the four-week study.

Halneuron® CINP Phase 2b Trial ("HALT-CINP") Overview (NCT06848348)

HALT-CINPis a randomized, phase 2b clinical trial evaluating the safety and effectiveness of Halneuron® versus placebo in cancer patients with established neuropathy due to a previous platinum or taxane based chemotherapy regimen. Participants receive 8 sub-cutaneous doses of Halneuron® or placebo over a 14-day period and will be followed for a total of 28 days for safety and effectiveness. The primary endpoint for this study is the change from baseline to week four in the weekly average of daily 24-hour recall pain intensity scores. The study is being conducted at approximately 25 sites in the US. Secondary measures will assess Halneuron's® treatment effects on sleep, fatigue, neuropathy symptoms and overall patient health.